Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.

About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

InvestorsChris Brinzey ICR Westwickechris.brinzey@westwicke.com 339-970-2843

MediaJon YuICR Westwickejon.yu@westwicke.com475-395-5375

Grafico Azioni Climb Bio (NASDAQ:CLYM)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Climb Bio
Grafico Azioni Climb Bio (NASDAQ:CLYM)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Climb Bio